Skip to main content

Table 3 Percent changes in cerebrospinal fluid amyloid-β fragment levels from baseline at day 28 across treatment groups

From: Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

Safety analysis set

Caucasian

Japanese

Early AD

Preclinical AD

Percent change from baseline at day 28

Placebo

JNJ-54861911

Placebo

JNJ-54861911

10 mg

50 mg

10 mg

50 mg

CSF Aβ1–37 (ng/L), n

12

15

14

4

2

3

 Mean (SD)

0.16 (10.753)

− 66.87 (6.851)

− 95.10 (4.501)

− 19.45 (5.529)

− 61.60 (3.741)

− 89.82 (2.385)

 Median (range)

0.31 (− 19.8; 19.4)

− 67.36 (− 81.1; − 52.1)

− 96.62 (− 99.4; − 87.7)

− 18.82 (− 26.2; − 14.0)

− 61.60 (− 64.2; − 59.0)

− 89.31 (− 92.4; − 87.7)

 95% CI of mean

(− 6.68; 6.99)

(− 70.67; 63.08)

(− 97.70; − 92.50)

(− 28.25; − 10.65)

(− 95.22; − 27.99)

(− 95.75; − 83.90)

 LS mean

0.29

− 66.94

− 95.13

− 19.89

− 62.45

− 88.67

 Difference of LS means (SE)

 

− 67.23 (3.103)

− 95.42 (3.106)

 

− 42.55 (4.011)

− 68.78 (4.105)

 95% CI

 

(− 73.52; − 60.94)

(− 101.71; − 89.12)

 

(− 52.86; − 32.24)

(− 79.33; − 58.23)

CSF Aβ1–38 (ng/L), n

13

15

15

6

6

6

 Mean (SD)

− 5.58 (27.514)

− 58.82 (7.183)

− 87.93 (3.511)

− 10.70 (7.618)

− 62.37 (18.712)

− 83.35 (4.890)

 Median (range)

− 2.21 (− 91.3; 19.2)

− 57.82 (− 76.5; − 50.9)

− 88.88 (− 91.4; − 82.4)

− 8.59 (− 21.8; − 3.0)

− 57.12 (− 99.7; − 50.4)

− 82.84 (− 88.9; − 76.1)

 95% CI of mean

(− 22.20; 11.05)

(− 62.80; − 54.85)

(− 89.87; − 85.98)

(− 18.69; − 2.70)

(− 82.01; − 42.74)

(− 88.48; − 78.22)

 LS mean

−7.48

− 57.34

− 87.76

− 10.21

− 62.95

− 83.26

 Difference of LS means (SE)

 

− 49.86 (6.095)

− 80.28 (5.920)

 

− 52.74 (7.746)

− 73.05 (7.229)

 95% CI

 

(− 62.19; − 37.53)

(− 92.25; − 68.31)

 

(− 69.35; − 36.12)

(− 88.56; − 57.55)

CSF Aβ1–42 (ng/L), n

13

15

15

6

4

6

 Mean (SD)

2.36 (14.942)

− 51.86 (11.611)

− 82.48 (4.852)

− 11.79 (10.105)

− 61.22 (7.510)

− 81.51 (3.076)

 Median (range)

1.08 (− 15.1; 41.7)

− 52.08 (− 72.8; − 31.2)

− 82.90 (− 90.4; − 73.5)

− 11.52 (− 26.1; 2.0)

− 60.78 (− 69.4; − 53.9)

− 81.90 (− 84.9; − 78.1)

 95% CI of mean

(− 6.66; 11.39)

(− 58.29; − 45.43)

(− 85.17; − 79.79)

(− 22.39; − 1.18)

(− 73.17; − 49.27)

(− 84.74; − 78.28)

 LS mean

1.40

− 51.92

− 81.58

− 11.64

− 61.45

− 81.50

 Difference of LS means (SE)

 

− 53.32 (3.864)

− 82.97 (3.905)

 

− 49.81 (5.191)

− 69.86 (4.509)

 95% CI

 

(− 61.13; − 45.50)

(− 90.87; − 75.07)

 

(− 61.12; − 38.50)

(− 79.69; − 60.04)

  1. Abbreviations: AD Alzheimer’s disease, Amyloid-beta, CSF Cerebrospinal fluid, LS Least squares